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Abstract: We propose a mathematical model to describe enzyme-based tissue degradation
in cancer therapies. The proposed model combines the poroelastic theory of mixtures with the
transport of enzymes or drugs in the extracellular space. The effect of the matrix degrading
enzymes on both the tissue’s composition and its mechanical response is included in the model.
Numerical simulations in 1D, 2D and axisymmetric (3D) configurations show how an injection of
matrix degrading enzymes alters the porosity of a biological tissue. We eventually exhibit the main
consequences of a matrix degrading enzyme pretreatment in the framework of chemotherapy: the
removal of the diffusive hindrance to the penetration of therapeutic molecules in tumors and the
reduction of interstitial fluid pressure which improves transcapillary transport. Both effects are
consistent with previous biological data.
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Un modèle basé sur la mécanique des milieux continus pour
la dégradation tissulaire par traitement enzymatique dans
les thérapies contre le cancer
Résumé : On propose un modèle pour décrire la dégradation tissulaire par traitement enzy-
matique dans les thérapies contre le cancer. Le modèle proposé combine la théorie des mélanges
en poroélasticité avec le transport des enzymes ou des médicaments dans l’espace extracellulaire.
L’effet des enzymes qui dégradent la matrice extracellulaire sur à la fois la composition du tissu
et sa réponse mécanique est inclu dans le modèle. Les simulations numériques dans des config-
urations 1D, 2D et en axisymétrie (3D) montrent comment une injection d’enzymes dégradant
la matrice extracellulaire altère la porosité d’un tissu biologique. On met en évidence à terme
les conséquences principales d’un traitement enzymatique dans les thérapies contre le cancer :
l’élimination de l’obstacle à la pénétration par diffusion de molécules thérapeutiques dans les
tumeurs et la réduction de la pression interstitielle, améliorant ainsi le transport transcapillaire.
Ces deux effets sont en accord avec des données biologiques existantes.
Mots-clés : Biologie mathématique, Poroélasticité, Dégradation de la matrice extracellulaire,
Pression interstitielle, Distribution tissulaire
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1 Introduction
1.1 Motivations
The use of macromolecules as therapeutic agents has come to the forefront in cancer research in
recent years. But macromolecular-based therapies are challenging, particularly those involving
intracellular targets. Indeed, one needs to consider the multiple biological barriers that stand
between the drug at its site of administration and its ultimate biological target [42, 31].
Figure 1: After its injection into the target tissue, a therapeutic agent encounters biological
barriers from extracellular environment toward the interior of the target cell.
Transport through the extracellular matrix (ECM) is a critical step in cell targeted drug delivery.
To reach the cell membrane, the therapeutic agent must diffuse through the ECM before being
fully degraded by the extracellular nucleases [21]. The ECM consists of a structural collagen
network embedded in a gel of glycosaminoglycans (GAGs) and proteoglycans. It is thought that
treatment with agents that degrade the ECM components, hyaluronidase for example [20, 37],
have the potential to increase the drugs penetration through the tissue and ultimately into cells
[73]. They are therefore used in medicine to improve drugs dispersion and delivery [12].
DNA vaccination. There are several physical approaches to perform nonviral gene therapy.
The simplest is the injection of naked DNA in the skeletal or cardiac muscle which leads to some
expression of the injected genes [74]. However, this expression is very low and very variable from
sample to sample. The main physical barrier encountered by DNA plasmids, the cell membrane,
can be overcome using DNA electrotransfer [5]. But in the case of skeletal muscle, there is another
limitation which is the access of the plasmid DNA to the muscle fiber surface. Controlled and
partial degradation of ECM with matrix degrading enzymes is used to increase the diffusion and
distribution of plasmid DNA into the muscle fiber. It has been shown that a pretreatment of
skeletal muscle with hyaluronidase followed by DNA electrotransfer improves gene expression
[63, 1, 61].
Inria
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Chemotherapy. Delivery of drugs to tumor cells occurs by two independent mechanisms:
diffusion and convection. However, the composition and structure of tumor-derived ECM can
slow down the movement of therapeutic molecules within the tumor [33, 24, 49]. In addition,
the disorganized vascular network and the absence of functional lymphatics cause increased
interstitial fluid pressure (IFP), which is a major obstacle to transcapillary transport [7]. As
far as diffusion is concerned, it was proven that an intratumoral injection of matrix degrading
enzymes removes diffusive hindrance to the penetration of therapeutic molecules in tumor models
[30, 36]. As far as convection is concerned, IFP may be temporarily reduced by degrading the
tumor ECM. It has been shown that collagenase and hyaluronidase reduce IFP, thereby improving
the uptake and distribution of molecules within solid tumors [28, 29, 19].
1.2 Main results
Need of numerical models. From the biological point of view, the effects of matrix degrading
enzymes on drug transport is well known. However, the litterature suffers from a lack of models
describing the active transport of those enzymes in the extracellular medium and the resulting
changes on the ECM. The aim of this paper is to provide a mathematical model that addresses
this phenomenon in order to offer a better understanding of the physical involved phenomena.
The model consists of a non-linear system of partial differential equation (PDEs). It is derived
directly from physical conservation laws. Constitutive relations are added to close the system.
The derivation’s steps are presented in Figure 2. We adopt a poroelastic approach to model the
mechanics of a biological tissue. This choice is made to take into account the swelling of the
tissue when fluid is added by injection. It is also in accordance with the studies stating that
biological tissue deformations are not negligible in numerical models describing drug delivery
[68]. This choice implies to first derive equations with Eulerian formalism and then reduce them
to a fixed reference domain via a suitable change of variables in order to make the numerical
processing possible. In addition, equations on the volume fractions of each component of the
tissue are included to take into account the structural changes. In the end, the main variables
of interest of the model are the three different volume fractions, the interstial pressure, the
displacement and the concentrations of enzyme and therapeutic agent respectively. The final
formulation of the model, system (55), is displayed in Section 3. To our knowledge, this is
the first model describing the alteration of a poroelastic medium produced by chemical species
injected directly in the medium. Alteration of a porous media is taken into account in [2, 58]
but within a rigid structure. Many mathematical models of passive transport into a poroelastic
medium do not take into account exchanges between phases [10, 68]. In [35, 46, 45], models
including exchanges between phases are presented on closed poroelastic mixtures (no external
sources or sinks). However, the changes are not mediated by external species. In [65, 66], magma
is modeled as a poroelastic medium with varying porosity due to temperature changes. However,
those changes are assumed to be infinitesimal. In [22, 6], poroelastic models taking into account
ECM degradation by matrix degrading enzymes produced by tumor cells are presented within
the particular framework of tumor growth. Nevertheless, these models have a very different
focus, namely showing the formation of fibrosis. They also make slightly different assumptions:
the ECM is rigid, the matrix degrading enzymes are produced by tumor cells and the cells’
movement is the one of an elastic fluid. The goal of the paper is to derive a model that combines
the effect of an injection of ECM degradation enzyme with a poroelastic macroscopic model
of biological tissue (skeletal muscle or tumor tissue), and to provide a numerical method that
allows to simulate the complete model in 1D-, 2D-, and axisymmetric configurations in order to
compare the results with the qualitative data available in the litterature. Let us note that the
long-term goal of the project is to provide a first step towards the numerical optimization of drug
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delivery with enzyme pretreatment.
Mass balance on fluid (13c)
Mass balance law on ECM
(13a)
Mass balance law on cells
(13b)
Momentum balance law on
fluid phase (17a)
Momentum balance law on
solid phase (17b)
Mass balance law on
enzyme’s concentration (25)
Mass balance law on
therapeutic agent’s
concentration (29)
Volume fraction of fluid
(Porosity) (55a)
Volume fraction of ECM (55f)






Constitutive Relations - Darcy
(30), Hooke (33), Starling
(31)
Figure 2: Schematic description of the derivation’s method of the model. The first set of boxes
contain the set of conservation laws and constitutive relations considered while the other boxes
contain the final equations on the variables of interest derived from the physical laws. The
numbering refers to the corresponding equations in their final form stated further in the article.
Numerical simulations illustrating biological phenomena. After testing the model with
a set of numerical simulations to investigate the effect of the new parameters added (Figures
12 and 14), we use the model to describe two situations: the incubation of a spheroid into an
ECM degradation enzyme and the intratumoral injection of enzyme in vivo. We observe that,
in the first test case, given the dependency of the diffusion tensor on the porosity variable [48],
a pretreatment with ECM degradation enzyme affects the distribution of therapeutic agents,
thereby improving the diffusion process. Where without pretreatment, the macromolecules stay
mainly at the periphery of the spheroid, a pretreatment with hyaluronidase permit to obtain a
wider distribution (Figure 3).
In the second case, given the dependency of the pressure on the porosity variable, an intratumoral
injection of enzyme results in a reduction of the IFP. This reduction depends on the enzyme’s
Inria
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Figure 3: Comparison between experimental doxuribicin fluorescence (left, data from [43]) and
numerically simulated (see Figure 18 in Section 5) concentration of anticancer agent in a spheroid
previously incubated with hyaluronidase (B) or not (A).
concentration and reaches a maximum value, a further increase of the dose resulting in a smaller
reduction, which is in accordance with the experiments (Figure 4).





















Figure 4: Comparison between experimental IFP (left, data from [29]) and numerically simulated
IFP (see 5.3.4). Normalized interstitial fluid pressure is represented in both cases as a function
of time after intratumoral injection of 150 U, 500 U, 1500 U and 3000 U hyaluronidase in tumors
compared to no pretreatment (intratumoral injection of saline solution).
It also appears that a pretreatment with ECM degradation enzyme affects the distribution of
therapeutic agents, thereby increasing its area of action by improving both the diffusion and the
convection processes. This is once more in accordance with the experiments (data from [29]).
Indeed, without pretreatment, the macromolecules stay only at the periphery of the tumor, the
transcapillary transport being greatly reduced by the high IFP inside the tumor. A pretreatment
with hyaluronidase permit to obtain a wider distribution. The molecules are thus distributed all
over the tumor (Figure 5).
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Figure 5: Comparison between experimental distribution of anticancer fluorescent agent (left,
data from [29]) and numerically simulated concentration of agent. In case A, no pretreatment
was previously performed on the tissue whereas in case B, the tissue was pretreated with 1500
U hyaluronidase.
1.3 Outline
In this paper, we construct a non-linear spatio-temporal model for the active transport of ECM
degradation enzyme into a poroelastic biological tissue coupled with the passive transport of
therapeutic agents. Section 2 is devoted to a precise description of our model following the
scheme presented in Figure 2. It is divided in two parts: in the first part, we derive some
equations from physical conservation laws, while in the second part, we conclude the formulation
of our model stating some constitutive relations. Section 3 is devoted to the simplification of
the model. We formulate the equations of the model in a fixed reference domain and assume
a small displacement hypothesis that simplify the numerical processing. Section 4 contains the
numerical scheme used to solve our PDE simplified model. The main features of the numerical
model are then investigated in 1D- and 2D-configurations. We conclude by numerical simulations
that corroborate experimental results in the framework of solid tumors in Section 5. To the best
of our knowledge, it is the first time that a PDE model describes the effect of an injection of ECM
degradation enzyme respectively on porosity, interstitial pressure and drug delivery. Calibration
of the model with experimental data are planned in forthcoming works.
2 Derivation of the model
2.1 Framework
Modeling the behavior of porous media in which different continua interact at the microscopic
level is not an easy task. In the current literature the mechanics of a porous medium is typically
described by two different approaches: the averaging approach and the macroscopic approach
[62], also known as mixture theory. The basic premise of the mixture theory is that the space
occupied by a mixture is occupied co-jointly by the various constituents of the mixture, each
considered as a continuum of its own. Thus, at any point of the space occupied by the mixture,
there will be a particle belonging to each constituent [35].
We let x and t denote the space and time variables, respectively. To simplify notations, we omit
the dependence of all variables and model parameters on x and t, except otherwise stated.
We denote by Ω0 = Ω(0) ⊂ Rd (d = 1, 2, 3) the initial spatial configuration, by Ωt = Ω(t) the
configuration at time t and by T the final time of the experiment.
The biological tissue is considered as a binary mixture of a solid and an interstitial fluid. The
Inria
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solid phase consists of cells and extracellular matrix (ECM). In what follows, the index ζ refers
to one of the three constituents of the tissue: the fluid (f), the ECM (E) or the cells (). The
index s stands for the solid phase (ECM + cells). The density of the ζth constituent is denoted
by ρζ . It represents the mass of the ζth constituent per unit volume of the mixture. The density
for the ζth constituent in a homogeneous state is denoted by ρRζ . It represents the mass of the





is the volume fraction of the mixture occupied by the ζth constituent. This definition coincides
with the classic definition given by [14]. The following standard assumptions on the mixture are
considered.
Assumption 1. (Saturation) The mixture is fully saturated, i.e.
ϕE + ϕ + ϕf = 1 ∀x ∈ Ω, ∀t > 0 (2)
This saturation condition excludes the possibility of the formation of voids or air bubbles inside
the medium.
Assumption 2. (Incompressibility) The liquid is incompressible in its pure state i.e. the density
of the liquid in a homogeneous state is assumed to be a constant, namely
ρRf (t, x) = ρ
R,0
f (t, x) ∀x ∈ Ω, ∀t > 0. (3)
Assumption 3. All the solid matrix constituents (cells and ECM) have the same density in a
homogeneous state:
ρRE (t,x) = ρ
R
 (t,x) = ρ
R
s (t,x). (4)
Assumption 4. (Slight compressibility) The solid phase (ECM + cells) is slightly compressible
in its pure state i.e. the density of the solid constituents in a homogeneous state can be written
as [23]:
ρRs (t,x) = ρ
R,0
s (t,x)(1 + s0(p(t,x)− p(0,x))), ∀x ∈ Ω, ∀t > 0, (5)
where
s0(p(t,x)− p(0,x)) 1, ∀x ∈ Ω, ∀t > 0, (6)
and where p is the interstitial fluid pressure and where ρR,0s is a constant. s0 can be related to
the specific storage coefficient that appears in Biot’s constitutive theory of consolidation [15].
Assumption 5. (Mass exchanges) We assume that mass exchanges occur only among cells/ECM
and fluid, meaning that degrading ECM is detoriated into extracellular fluid, and conversely that
the latter is consumed whenever ECM is created.
Assumption 6. (Fluid source term) Fluid is exchanged between interstitial space and the blood
or lymph vessels: the fluid source term is then assumed to be driven by the average transmural
pressure. If fluid is directly injected in the tissue, another external source of fluid is added during
the injection.
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2.2 Balance laws
In this section we give the set of conservation laws that constitute our proposed mathematical
picture of the mechanobiological properties of the tissue using the Eulerian formalism. All the
solid matrix constituents (cells and ECM) are experiencing the same motion. Thus vE(t,x) =
v(t,x) = vs(t,x). The motion function refers to the solid phase, so it is useful to use the
Eulerian velocity of the fluid with respect to the solid phase defined by
w(t,x) = vf (t,x)− vs(t,x). (7)
2.2.1 Mass balance for each component of the mixture
The mass of the ζth constituent can change due to
1. the flux caused by the motion at the velocity vζ of the constituent,
2. the production that accounts for possible mass conversion between constituents at a certain
rate Qζ [35],




+∇ · (ρζvζ)− ρζQζ − Sζ = 0, (8)
where the source term Sζ is given as
Sζ = ρRζ Σζ . (9)
Using definition (1) we get
∂(ρRζ ϕζ)
∂t
+∇ · (ρRζ ϕζvζ)− ρRζ ϕζQζ − Sζ = 0.
To translate Assumption 5, we assume the following constraint [35]
ρRs ϕEQE + ρ
R
f ϕfQf = 0. (10)
The production terms Qf and QE introduced here describe the mechanisms of addition and/or
removal of mass for each species constituting an isolated tissue. We assume that the ECM is
degraded proportionally to the enzyme’s concentration [3], becoming fluid, and that the tissue
recovers towards its initial state.
It is then relevant to choose the production term QE as
QE = −Kϕfcenz + ar (ϕf − ϕf (0,x)) . (11)
where K is the rate of deterioration of the solid phase when in contact with the enzyme, rep-
resented by its concentration in the fluid phase ϕfcenz. As the ECM is recovered a certain time
after the injection of the enzyme [41, 38], the second term in the expression of QE represents this
reconstitution of the tissue towards its initial state, at a certain rate of natural reconstruction
ar.
To translate Assumption 6, we choose the fluid source term as
Σf = Q
tot
inj +Qvas −Qlym where Qtotinj = Qenzinj +Qdruginj , (12)
where Qenzinj represents the injection term of enzyme, Qdruginj represents the injection term of ther-
apeutic agent, Qvas is the transcapillary flow and Qlym is the lymphatic drainage.
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The mass balance equations for the tissue’s constituents are then expressed by the following
coupled system of PDEs in Ωt × (0, T ):
∂
∂t
(ρRs ϕE) +∇ · (ρRs ϕEvs) = ρRs ϕE(−Kϕfcenz + ar (ϕf − ϕf (0,x))),
∂
∂t
(ρRs ϕ) +∇ · (ρRs ϕvs) = 0,
∂
∂t







Figure 6: Schematic description of exchange pathways and production terms of the different
phases.
2.2.2 Total mass balance for the mixture
Summing equations (1/ρR,0s )× (13a), (1/ρR,0s )× (13b) and (1/ρRf )× (13c), using Assumptions 1















ϕE(−Kϕfcenz + ar (ϕf − ϕf (0,x))).
(14)
This equation expresses the conservation of the total mass of the tissue. A simple manipulation















ϕE(−Kϕfcenz + ar (ϕf − ϕf (0,x))).
(15)
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Remark 1. The term ϕss0
(
∂p
∂t +∇p · vs
)
in Equation (15) comes from Assumptions 5 and 6. If
the density in an homogeneous state of the solid phase were assumed to be a constant, this term
would vanish.
2.2.3 Momentum balance for each component of the mixture
The momentum of the ζth constituent can change due to
1. the momentum flux caused by the motion at the velocity vζ of the constituent,
2. contact forces within the constituent acting through the boundary,
3. contact forces due to the interaction with the other constituents within the domain through
the interface separating the constituents,
4. momentum supply related to phase changes,
5. momentum supply related to external sources or sinks of mass,
6. body forces.
One can then write the following local form of the momentum balance in conservative form
∂
∂t
(ρζvζ) + ∇ · (ρζvζ ⊗ vζ) = ∇ · σζ + ρζb + πζ + ρζQζvζ + Sζvζ ,
where
• σζ is called the partial stress,
• πζ is called the interaction force,
• b is an external force applied to the system e.g., extra pressure due to the injection.





vζ + vζ ·∇vζ
)
= ∇ · σζ + ρζb + πζ , (16)
where the inertial term on the left-hand side can usually be neglected when describing biological
tissues [8, 9]. Let’s recall that all the solid matrix constituents (cells and ECM) experience
the same overall motion, so we can simplify the momentum balance equations for the tissue’s
constituents into the a coupled system of PDEs to be solved in Ωt × (0, T ):{
∇ · σf + ρRf ϕfb + πf = 0,
∇ · σs + ρRs ϕsb + πs = 0,
(17a)
(17b)
where (17b) is the equation resulting from the sum of (16) for ζ = E , , and expresses the total
momentum of the solid phase as a whole. In the case of a saturated mixture, it can be proved
that [18] {




where σEs is the effective stress tensor of the solid phase of the tissue, whose form will be
discussed in Section 2.3, and where p = p(t,x) is the pressure exerted by the fluid phase and I is
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the identity tensor. The isotropic stress −pI accounts for the coupling, typical of poroelasticity,
between the low of the fluid and the deformation of the solid matrix, and in particular describes
the contribution to the stress due to the fluid pressure within the structure.
The quantities σζ , ζ = s, f , are the total stress tensors of the solid and fluid phases. As usual,
we neglect the effective stress tensor of the fluid, meaning that we assume that the internal fluid
viscosity is negligible compared with the friction between the fluid and the solid matrix [9].
We observe that, for all t ∈ (0, T ) and at all x ∈ Ω, it holds [57]
πs(t,x) + πf (t,x) = 0. (19)
2.2.4 Total momentum balance for the mixture
Summing equations (16) for ζ = s, f and using (18), we get
∇ · (ϕsσEs ) + (ρf + ρs)b = ∇p. (20)
This equation expresses the conservation of total momentum of the tissue. In what follows, we
will assume the external body forces to be zero, such that equation (20) becomes
∇ · (ϕsσEs ) = ∇p. (21)
2.2.5 Mass balance for ECM degradation enzyme’s concentration
Another fundamental quantity of interest from the modeling point of view is the concentration
in ECM degradation enzyme, such as hyaluronidase or collagenase, per unit volume within the
fluid phase of the tissue, cenz = cenz(t,x). However, the concentration cenz has to be related
to the volume ratio occupied by the interstitial fluid. Finally the relevant entity for an overall
balance over the whole tissue is the reduced (or weighted) concentration, e.g. Cenz = ϕfcenz.
The mass balance system (13) for the solid and fluid phases of the tissue is thus accompanied
by a corresponding continuity equation for the hyaluronidase concentration that is transported
throughout the tissue by the interstitial fluid. We consider that the reduced concentration can
change due to
1. the motion of the fluid at the velocity vf ,
2. the diffusive flux,
3. natural degradation and/or the intake due to the source.
Therefore, the following reaction-convection-diffusion equation reads
∂
∂t
(ϕfcenz) +∇ · (ϕfcenzvf ) = −∇ · (ϕf jfenz)− kd,effenz ϕfcenz + Senz, (22)
where
• jfenz is diffusive flux inside the liquid phase,
• kd,effenz is the net natural degradation effective rate of the enzyme in the interstitial fluid,
• Senz is the contribution consecutive to the injection (directly into the tissue or intravenously)
of enzyme.
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Fick’s law states that the diffusive flux can be assumed to be proportional to the concentration
gradient in the liquid, that is
jfenz = −Dfenz∇cenz, (23)
where Dfenz is the effective diffusion tensor in the liquid, that we choose to be a tensor linearly




Hence, equation (22) in terms of Cenz = ϕfcenz becomes
∂Cenz
∂t









− kd,effenz Cenz + Senz. (25)
2.2.6 Mass balance for drug concentration
The main quantity of interest from the modeling point of view is the concentration in therapeutic
agent per unit volume within the fluid phase of the tissue, cdrug = cdrug(t,x). As previously, the
concentration cdrug has to be related to the volume ratio the interstitial fluid. The relevant
entity for an overall balance over the whole tissue is the reduced (or weighted) concentration,
e.g. Cdrug = ϕfcdrug. The continuity equation for the therapeutic agent’s concentration that is
transported throughout the tissue by the interstitial fluid can be deduced considering that the
reduced concentration can change due to
1. the motion of the fluid
2. the diffusive flux
3. natural degradation and/or the intake due to the source.
Therefore, the following reaction-convection-diffusion equation can be deduced
∂
∂t
(ϕfcdrug) +∇ · (ϕfcdrugvf ) = −∇ · (ϕf jfdrug)− kd,effdrugϕfcdrug + Sdrug, (26)
where
• jfdrug is diffusive flux inside the liquid phase,
• kd,effdrug is the net natural degradation effective rate of the drug in the interstitial fluid,
• Sdrug is the contribution consecutive to the injection (directly into the tissue or intra-
venously) of drug.
As before, Fick’s law states that the diffusive flux can be assumed to be proportionnal to the
concentration gradient in the liquid, that is
jfdrug = −Dfdrug∇cdrug, (27)
where Dfdrug is the effective diffusion coefficient in the liquid, that we choose to be linearly




Hence, using (13c), equation (22) simplifies to
∂Cdrug
∂t









− kd,effdrugCdrug + Sdrug. (29)
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2.3 Constitutive equations regarding the mechanical and fluid subsys-
tems
2.3.1 Darcy’s law
We assume the relative velocity to be expressed by Darcy’s law [4, 10, 6, 9]
ϕfw = ϕ(vf − vs) = −κ∇p (30)
where κ is the permeability tensor.
2.3.2 Starling’s law
The transcapillary flow and the lymphatic drainage are taken into account in (12). Both rates
Qvas andQlym can be evaluated throught Starling’s law. A complete description of the formulation




(pv − p), (31)
where Lp and LPL are the hydraulic conductivities of the microvascular wall and of the lymphatic
wall respectively; S/V and SL/V are the surface area per unit volume of the vasculature and of
the lymphatics respectively; and where pv is the driving pressure. Equation (31) will be written
as
Qvas −Qlym = γ(pv − p), (32)
where γ = (LpS + LPLSL)/V will be assumed to be a constant.
2.3.3 The linear elasticity framework
To complete our derivations of the equations of motion, we must know (or assume) the relation-
ships (constitutive laws) between effective stress and strain. The classical theory of elasticity
deals with the mechanical properties of elastic solids for which the stress is directly proportional
to the stress in small deformations. Linear elastic theory can be satisfactorily applied for mod-
eling the mechanical properties of biological media [34, 50, 10, 16]: namely, we assume that
biological tissues are nearly linear elastic under small strain and follow a constitutive law based
on Hooke’s law. Specifically, a Hookean elastic solid is a solid that obeys Hooke’s Law, that
states that the first Piola-Kirchhoff stress tensor SEs is such that
SEs;ij = Cijklεkl (33)
where Cijkl is the stiffness tensor and where ε is the infinitesimal strain (48) defined later in
Section 3.
Remark 2. For most materials, the linear elasticity framework is only valid for small displace-
ments [59].
Remark 3. In biomechanics, biological tissues are thought to be better described as viscoelastic
solids [34, 27]. However, for the sake of simplicity, we choose here to stay within the framework
of the linear elasticity theory.
The first Piola-Kirchhoff stress tensor is then related to the Cauchy stress tensor [11] via the
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Isotropic media. In the most simple symmetry case of an isotropic elastic solid, the material
has only two independent elastic moduli, called the Lamé constants, λ and µ . In such a medium
the elastic properties at any point are independent from direction. The Lamé constants are
related to the stiffness tensor Cijkl by
Cijkl = λδijδkl + µ (δikδjl + δilδjk) ,
which gives us the following form for the effective stress SEs
SEs = 2µε+ λTr(ε)Id. (35)








drugId, κ = κId. (36)
Transverse isotropic media. It is now well established that anisotropy plays a major role in
the mechanical properties of biological media such as muscles, tendons or bones [60]. The most
simple anisotropic model is the transverse isotropy. A transversely isotropic tissue is characterized
by the existence of a single plane of isotropy and one single axis of rotational symmetry, the
normal to the isotropy plane. Skeletal muscle, for instance, consists of hundreds to thousands,
sometimes millions, of long, multinucleated fibers organized and held together by an ECM thus
it is relevant to model it as a transverse isotropic media.
In the case of a transverse isotropic medium in 2D, relation (33) reduces to (35) in the plane of
isotropy (xy). If we consider the plane (xz), (33) can be written in the following fashionSEs;11SEs;33
SEs;13
 =





It has been reported [70] that the permeability κ depends on many factors including the geometry.
Orientation can affect κ, with perpendicular fibers providing a larger resistance to flow κ⊥ than







As far as the diffusion tensors are concerned, it was also reported [25, 26] that the diffusion
coefficient parallel to a skeletal muscle fiber’s long axis D0enz,// (resp. D0drug,//) is greater than the
diffusion coefficient perpendicular to the fiber’s long axis D0enz,⊥ (resp. D0drug,⊥). Consequently,













The degree of porosity has a significant impact on the net natural degradation effective rate of
the enzyme or the drug in the interstitial fluid kd,effenz , k
d,eff
drug . The effects are both attributed to
a wall effect and a surface area effect because the media with lower porosities or larger pores
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possess thicker pore walls and smaller surface area, which depress the diffusion of degradation








where kdenz and kddrug are positive constants.
2.3.5 Source terms.
Let the index ω denote either of the chemical species of interest (enzyme and/or drug).
Injection. If the chemical specie is directly injected in the tissue, we can choose to take the
source term as
Sω = cωinjQωinj, (41)
where cωinj is the value of the specie concentration injected, which is assumed to be a constant.













where qωinj, σxi are positive constants and where (x01, . . . , x0d) indicate the coordinates of the in-
jection point.
Incubation. If the tissue is incubated in the chemical specie, the source term Sω is taken as
zero and and we choose instead to apply a non homogeneous Dirichlet boundary condition on
Cω (cf section 5).
Transcapillary transport. If the chemical specie is injected intravenously, we choose to take
the source term accordingly with the pore model for transcapillary exchange via convection stated
in [13]
Sω = (1− γc)(Qvas −Qlym)cωv , (43)
where γc represents the coupling between fluid and solute and cωv is the plasma concentration of
the chemical specie. In the numerical simulations of section 5, for the sake of simplicity,
cωv = c
ω
v,0 χ|t1≤t≤t2 , (44)
where cωv,0 is a constant, and [t1, t2] is the time interval of presence in the capillary network. cωv
can be chosen to follow any pharmacokinetic model of interest.
3 Formulation of the poroelastic model in a fixed domain
3.1 Kinematics of the mixture
The motion of the constituents is described by the position occupied at time t by the particle
labelled X
x = Φ(t,X), (45)
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Figure 7: Deformation from the fixed domain Ω0 via the application Φ
X being the position of the particle in the reference configuration Ω0. The function Φ(t, .)
represents a mapping from initial (undeformed) configuration Ω0 to the present (deformed) con-
figuration Ωt.
The velocity of a particle belonging to the ζth constituent, often termed the Lagrangian velocity,
Vζ(t,X), is the time rate change of the particle position holding X fixed. As we will use the
Eulerian formalism to state conservation equations, we recall that the Eulerian velocity at time
t and position x, vζ(t,x), is given by
vζ(t,x) = Vζ(t,X) when x = Φ(t,X). (46)











We also set B := A−1 and J := det(A). We stated that all the solid matrix constituents (cells
and ECM) experience the same overall motion [45]. The displacement vector of the solid phase





We also define the associated infinitesimal deformation of the volume surrounding the point X














+ (vs.∇) (.). (49)
3.2 Change of variables
From now on, the medium is assumed to be isotropic. The formulation in a transverse isotropic
medium will be similar as only equation (55b) will change. To reduce the governing equations
to the reference fixed domain Ω0, we introduce a suitable change of variable, which is given by
the motion function (45): x = Φ(t,X).
If u(t,X) = x−X is the displacement vector, Φ is given by
Φ(t,X) = X + u(t,X). (50)
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Let us set
f(t,X) := ϕf (t,Φ(t,X)), gs(t,X) := ϕs(t,Φ(t,X)),
gE(t,X) := ϕE(t,Φ(t,X)), g(t,X) := ϕ(t,Φ(t,X)),
P (t,X) := p(t,Φ(t,X)), Pv(t,X) := pv(t,Φ(t,X)),
h(t,X) := Cenz(t,Φ(t,X)), c(t,X) := Cdrug(t,Φ(t,X)),
Recall that we have already from Section 2.3









−T with SEs = 2µε+ λTr(ε)Id, (52)
since we consider the isotropic case. Moreover, every time and space derivative are affected by






, ∇x ϕf = B∇X f. (53)
3.3 Non-dimensionalization
We state that from now ∇ denotes the operator ∇X = (∂X1 , . . . , ∂Xd)T . Denote by l0 the typical
length of the porous medium. We non-dimensionalize the governing equations by letting







P = (λ+ 2µ)P , h = c0h, c = c0c,
where we use bars to denote the dimensionless variables. The dimensionless Piola-Kirchhoff and
Cauchy stress tensors are defined as SEs = S
E
s /(λ + 2µ) and σEs = σEs /(λ + 2µ), respectively,






























D0drug, kddrug = αk
d
drug.
We choose the (λ + 2µ) parameter as a natural pressure scale; by this choice the dimensionless
elastic parameters λ, µ are of order 1 [44].
RR n° 9030
20 Manon Deville & others
3.4 Simplification of the model
The governing equations in Ωt can be reformulated on the fixed reference domain Ω0 dimension-
less. The first advantage of this process is to obtain a system of equations in a fixed reference
domain in order to make the numerical processing possible. Second, the constitutive relation on
the stress tensor SEs is given in the lagrangian coordinates (t,X), so it is natural to work within
this system of coordinates. The third benefit is to elude the transport equations of the three
different volume fractions: in the fixed reference domain, those equations reduce to ordinary
differential equations. In particular, we don’t have to state boundary conditions on the porosity.
The calculus in the general case can be found in Appendix A. For the sake of simplicity, we will
assume that our system undergo very small perturbations (see Remark 2). One can see then
that B = Id +M(∇u), where in the case of very small deformations, the coefficients of matrix








The equivalent system in Ω0 in dimensionless form in this simplified case reads



























































































Remark 4 (Dynamics added on porosity’s behavior). In previous studies, the porosity of
the medium (or volume fraction of fluid) is often regarded as a constant [10]. Models that include
porosity changes [54] have used the following relation between ∇ · u and ϕf :
f =
f(0,x) +∇ · u
1 +∇ · u ,
which is obtained traducing an hypothesis of infinitesimal displacement on the variation of vol-
ume, or more recently [68]
f = 1− (1− f(0,x))e−∇·u,
which is obtained from Equation (55e) in the case of a biphasic system with only incompressible
cells and incompressible fluid. However, in our case, since our main hypothesis is that the porosity
is not only affected by the deformation of the medium but mostly by the ECM degradation
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enzyme injected, we must derive an expression for the effective porosity directly from the mass
balance laws of the ECM and cells constituents.
An expression for the effective volume fraction occupied by cells can be derived from the volume
balance of the phase occupied by cells assuming the initial conditions g(0,x) = g0(x) and
∇ · u(0,x) = 0. Integrating Equation (55e),
g(t,x) = g0(x)e
−∇·u−s0(P−P 0). (56)
To obtain the effective volume fraction occupied by ECM, consider
g̃E = gEe
∇·u+s0(P−P 0). (57)
An equation for this quantity assuming the initial conditions ∇ · u(0,x) = 0, P (0,x) = P 0(x)








This equation reflects the fact that, regardless of the mechanical changes due to the displacement
and the compressibility of the tissue, the ECM is deteriorated when in contact with the ECM
degradation enzyme, but then reconstruct itself towards its initial state.
Figure 8: g̃E is plotted versus time for an ini-
tial volume fraction of ECM of 0.3 and for dif-
ferent concentrations of enzyme applied con-
tinuously during 30 minutes, regardless of the
space dependency. Both tendencies (degra-
dation during injection - reconstruction) can
easily be observed.




















The primary variables of the problem are the displacement u, the pressure P and the concen-
trations in ECM degradation enzyme h and in therapeutic agent c. Define the boundary of the
domain Ω, denoted Γ. We generically denote by n the normal to Ω outwardly directed from the
inside to the outside of the domain. Next, define the portions of the boundary Γu and Γt on
which displacement and stress are defined, such as Γu ∪ Γt = Γ and
u = uΓu on Γu and S
E
s n = t on Γt. (58)
Applying the condition SEs n = 0 to the boundary amounts to considering a free boundary, while
setting uΓu = 0 amounts to considering a fixed boundary.
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The portions of the boundary Γp and Γq are the parts of the boundary on which pressure and
pressure flux are specified, such as Γp ∪ Γq = Γ and
P = PΓp on Γp and ∇P · n = q on Γq. (59)
Setting a Dirichlet condition on the pressure amounts to considering a permeable boundary in
contact with a surrounding medium where the pressure is fixed, while applying the condition
∇P · n = 0 amounts to considering a wall boundary condition.
The portions of the boundary Γh and Γβ are the parts of the boundary on which the enzyme’s
concentration and flux are specified, such as Γh ∪ Γβ = Γ and{
h = hΓh on Γh,(
fD0enz∇h+ hJenz
)
· n = β1 on Γβ .
(60a)
(60b)
The same type of boundary conditions are applied to the therapeutic agent’s concentration and
flux {
c = cΓh on Γh,(
fD0drug∇c+ cJdrug
)





We first need to reduce the whole coupled system (55) to a sequence of linearized equations of
simpler form. We subdivide the time interval [0, T ] into N ≥ 1 uniform subintervals of length
∆t = TN , in such a way that the discrete time levels t
n = n∆t, n = 0, . . . , N , are obtained. We
set
∇ · u0 = 0, g0E = gE(0,x), g̃0E = gE(0,x), g0 = g(0,x), h0 = 0 and c0 = 0, (62)
and P 0 is set as the solution of the steady-state pressure equation:
−∇ · (κ∇P 0) = γ(pv − P 0), (63)
coupled with the boundary conditions (59).
For n = 0, . . . , N − 1, we perform the following iteration:
1. We obtain fn using (55a): fn = 1− gnE − gn , and we set gns = gnE + gn .
2. We obtain un+1 and Pn+1 solving the linear poroelastic system with the finite element
solver FreeFem++ [39], choosing P2 (resp. P1) elements for un+1 (resp. Pn+1) to guarantee
stable Galerkin approximation [32, 51] and discretizing in time with a first order backward
Euler scheme [52]. Note that having a parabolic equation on P , which is a consequence of
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supplied by the approximation of the boundary conditions (58) and (59)
{
un+1 = uΓu on Γu and S
E,n+1
s n = t on Γt,
Pn+1 = PΓp on Γp and ∇Pn+1 · n = q on Γq.
(65a)
(65b)








We obtain hn+1 and cn+1 solving the linear advection-diffusion-reaction equations still










































supplied by the following approximation of the boundary conditions (60) and (61):{




· n = β1 on Γβ ,




· n = β2 on Γβ .
(69a)
(69b)
4. We obtain gn+1E by first calculating
g̃n+1E =
g̃nE
1 + ∆t(Khn+1 + ar(f(0,x)− fn))
.










Remark 5 (Triangulation convergence tests). We checked numerically that the relative error
eh (resp. ef , eP ) on the total mass of enzyme (resp. the quantity of fluid, the mean pressure) at
t = 60 min decreases with order 1 when refining the mesh (Figure 9).
Remark 6 (Conservation of mass). A test case is performed to check if the total mass of
enzyme injected is conserved when its degradation rate is zero. When the degradation rate is
nonzero, the enzyme’s total mass remains positive, and after reaching a maximum amount at
the end of the injection, it decreases gradually till reaching zero as it has been observed in [53]
(Figure 10).
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Figure 9: Results from the triangulation convergence simulations in 1D at t = 60 min (simulations
from section 4.2). The relative error on
∫
Ω
Z(t = 60 min) dx with Z = h, f, P is plotted using
logarithmic scales on both the horizontal and vertical axes.


















(a) Numerical mass conservation of en-
zyme.

















(b) ECM degradation enzyme’s total
mass versus time when degradation
rate is nonzero.
Figure 10: First numerical results on the total mass of enzyme. Numerically, the mass is well
conserved when the degradation rate is zero, while the curve has the expected shape when the
degradation rate is nonzero.
4.2 Numerical tests in 1D
The computational domain. In this section, we formulate the poroelastic transport model
in a one-dimensional geometrical configuration (1D). Figure 11 shows a schematic representation
of the 1D reference domain we considered. Denoting by x the spatial coordinate, the region
x < 0 represents the tissue far away from the site of injection, the open interval Ω = (0, L) is the
tissue whereas the region x > L corresponds to the air surrounding the tissue.
Simulation Tests. What we want here is to understand the qualitative effect on the porosity
of a injection of ECM degradation enzyme. Consequently, we consider in this section system
(55) without equation (55g). In the simulations, γ is chosen so the initial pressure, derived from
equation (63), is a constant.
To test the capability of the model, simulations are performed on the homogenous domain rep-
resented in Figure 11. The border of the domain is divided in two parts: Γ = Γ0 ∪ Γf . On Γ0
(x = 0), Dirichlet boundary conditions are imposed, i.e. displacement u and concentration h are
set to zero, and pressure P is set to pv. On Γf (x = 1), a free boundary condition is imposed
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Figure 11: Schematic representation of the 1D reference domain.
on the displacement, i.e. SEs n = 0, while a wall condition is imposed on the pressure and the




· n = 0. Visualization with the software
FreeFem++ allows us to plot the porosity f and any other quantities of interest directly in a
changing domain thanks to the function movemesh [39].
The principal scope of this serie of numerical experiments is to understand the qualitative be-
havior of the porosity after an injection of ECM degradation enzyme. Four sets of simulation
tests are performed to investigate respectively the transport and effect of a passive substance
(like water), the sole effect of degradation of the ECM by the enzyme injected, the effect of
the enzyme on the ECM with recovery and the effect of the enzyme on the ECM with natural
degradation of the enzyme. The fifth set of simulations corresponds to investigating how all the
different effects interact together. Table 1 sums up these five different sets of simulations.




Simulation 1 0 0 0 Passive transport
Simulation 2 0.5 0 0 Effect on ECM
Simulation 3 0.5 0.01 0 Effect on ECM + Recovery
Simulation 4 0.5 0 0.001 Effect on ECM + Natural degradation
Simulation 5 0.5 0.01 0.001 Effect on ECM + Recovery + Natural degradation
Simulations are performed first on the computational domain described in Figure 11 and the
effects on the porosity f are investigated. Figures 12 represent the porosity of the medium at
four different times for each simulation: after 1 minute, 10 minutes, 30 minutes and 1 hour.
In the case of passive transport of water, the porosity remains equal to its initial value (0.1 in all
four simulations). In reality, the porosity varies a little bit because of the volume variation, but
when plotted between 0 and 1 it is not obvious and it seems legitimate to assume that the porosity
is a constant in this case (12a). In the second set of simulations, we want to investigate the sole
effect of degradation of the ECM by the enzyme, without recovery of the tissue and without
natural degradation of the enzyme. With K = 0.01, the effect of the enzyme on the ECM is
immediate: after 1 minute, the ECM around the injection site has deteriorated. Then, with
the diffusion of the enzyme, the area where the ECM deteriorates expands mostly towards the
boundary Γf as the enzyme flows out the domain through boundary Γ0, without ever overcrossing
the maximum value possible f + gE = 0.5 (12b). When we add a recovery dynamic, we observe
that at some point, the area where the ECM has deteriorated stops expanding and the porosity
tends to get back to its initial state (12c). In the fourth set of simulations, the recovery dynamic
is not considered anymore but we take into account the natural degradation of the enzyme. In
this case, the area where the ECM deteriorates starts expanding then reaches its equilibrium
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(a) Simulation 1
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(d) Simulation 4
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t = 10 min
t = 30 min
t = 1 h
(e) Simulation 5
Figure 12: Porosity changes at t = 1 min, 10 min, 30 min and 1 hour in the 1D case.
state (12d). In the last set of simulations, all effects are considered together (12e).
4.3 Numerical tests in 2D
The computational domain. Figure 13 shows a schematic representation of the 2D reference
domain we considered.
Figure 13: Schematic representation of the 2D
reference domain. As in the 1D case, the bor-
der of the domain was divided in two parts:
Γ = Γ0∪Γf . On Γ0, Dirichlet boundary condi-
tions were imposed, while on Γf , free bound-
ary conditions were imposed.
Simulation tests. As before, we consider in this section system (55) without equation (55g)
and γ is chosen so the initial pressure, derived from equation (63), is a constant. Parameters
K, ar and kdenz are set in order to mainly observe during the simulation’s time the deterioration
effect of the enzyme on the ECM. This second set of simulation tests in 2D consists mainly in
Inria
A model of enzyme-based tissue degradation 27
comparing the isotropic and transverse isotropic cases. As expected the main difference lies in
the shape of the area where the ECM has been deteriorated. These 2D simulations emphasize
mainly the possibility offered by the mathematical model we developed of considering anisotropic
media.
(a) Porosity at t = 1, 10, 30, 60 minutes in the 2D isotropic case
(b) Porosity at t = 1, 20, 60, 120 minutes in the 2D anisotropic case
Figure 14: Porosity changes at t = 1 min, 10 min, 30 min and 1 hour in the 2D case for K = 50,
ar = 0.0005 and kdenz = 0.0001.
5 Comparison with experiments: drug penetration in solid
tumors
5.1 Experimental framework
To be most effective, anticancer drugs must penetrate tumor tissue efficiently, reaching all cells
in a concentration suffcicient to exert a therapeutic effect. Nevertheless, the distribution of many
anticancer drugs in tumor tissue is incomplete, as physiological transport barriers can strongly
abate their efficiency [49, 71]. In particular, the composition and structure of the extracellular
matrix can slow down the movement of molecules within the tumor [55]. Degradation of the
ECM is assumed to improve the penetration of drugs. Delivery of drug to tumor cells occurs by
two independent mechanisms: diffusion due to the concentration gradient and convection due to
pressure gradient. It has been shown that both those mechanisms are enhanced when the tissue
is previously injected or incubated with ECM degradation enzymes such as hyaluronidase and
collagenase [29, 30, 28]. Multicellular spheroids are spherical aggregates of tumor cells that reflect
many properties of solid tumors, including the development of an ECM, therefore they have been
used to study the penetration of anticancer drugs into tumor tissue [49]. Experimental results
are consistent in showing limited drug penetration into spheroids [69]. A pretreatment with
hyaluronidase or collagenase was shown to increase the diffusion coefficient of larger molecules
in spheroids, and the enzymatic treatment also improved the diffusion in the case of smaller
molecules in tumor tissue [30], thereby improving the tissue’s sensitivity to cytotoxic drugs [67,
43]. Spheroids models allow to evaluate the influence of diffusion on drugs transport, but some
features of solid cancer such as variable IFP and the influence of convection (which commonly
occurs in the periphery of tumors) are not modeled [49]. In vivo, the disorganized vascular
network and the absence of functional lymphatics causes increased interstitial fluid pressure
(IFP), which is uniformly elevated throughout a solid tumor and drops precipitously in the tumor
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Table 2: Values of the model parameters in the simulations of Sections 4 and 5, except from K,
ar, kdenz otherwise specified. Parameters indexed with a ∗ have different values in Section 5 (see
Table 3).
Parameter Symbol Value Unit Reference
Typical lenght l0 10−2 m
Reference concentration c0 109 kg/m3
Density of fluid phase ρRf 10
3 kg/m3 [76]
Density of solid phase ρR,0s 1.09× 103 kg/m3 [72]
Specific storage coefficient s0 10−6 Pa−1
Injected concentration cenzinj 4× 10−2 U/µl [63]
Diffusion coefficient of the enzyme∗ D0enz 10−8 m2/s
Permeability κ 10−11 m2Pa−1s−1 [70]
Lamé first parameter λ 7.14× 105 Pa [77]
Lamé second parameter µ 1.79× 105 Pa [77]
Diffusion coefficient perpendicular to a fiber’s axis D0enz,⊥ 10−8 m2/s
Diffusion coefficient parallel to a fiber’s axis D0enz,// 1.5×D0enz,⊥ - [25]
Permeability perpendicular to a fiber’s axis κ⊥ 10−11 m2Pa−1s−1
Permeability parallel to a fiber’s axis κ// 1.5× κ⊥ -
Elastic constants (TI case) C1111 2.64× 106 Pa [47]
C1133 3.39× 106 Pa [47]
C1313 10
2 Pa [47]
C3333 4.4× 106 Pa [47]
Initial values Symbol Initial value Unit
Volume fraction of fluid ϕf (0,x) 0.1 -
Volume fraction of ECM ϕE(0,x) 0.4 -
Volume fraction of cells ϕ(0,x) 0.5 -
Network dilatation ∇.u(0,x) 0 -
Concentration in enzyme h(0,x) 0 Um−3
Pressure p(0,x) 0 Pa
periphery [40, 17]. The high IFP is a major obstacle to penetration of therapeutic molecules, as
the transcapillary pressure gradient is low, and an outward interstitial flux is generated toward
the periphery of the tumor due to the steep pressure gradient in the periphery of the tumor. It
has been shown that hyaluronidase and collagenase reduce IFP, thereby improving the tumor
uptake and distribution of molecules within solid tumors [29, 19]. The tumor (resp. spheroid) was
modeled as a sphere and consequently we chose to perform numerical simulations in axisymmetry.
We used the 2D computational domain shown in Figure 19. No calibration of the parameters
was done, our objective being to observe the qualitative effects of the incubation with ECM
degradation enzyme of a spheroid on diffusion on one hand, and of an intratumoral injection of
ECM degradation enzyme on transcapillary transport on the other hand.
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5.2 Effect of an ECM degradation enzyme on diffusion of therapeutic
agent
5.2.1 Boundary conditions
Define the portions of the boundary Γext, the surface of the spheroid, and Γint the inner bound-
aries. To take into account the axisymmetric geometry of the domain, we choose on the internal
boundaries Γint homogeneous Neumann conditions on P , h and c and we impose that the dis-
placement will only be radial. On the surface of a spheroid, there are no contact forces and the
pressure at the outer edge is the same as the pressure in the surrounding medium, that we set
to be equal to Pext.{
SEs n = 0 on Γext, u · n = 0 on Γint,
P = Pext on Γext, ∇P · n = 0 on Γint,
(70a)
(70b)
During the first hour, the spheroid is incubated with the enzyme, so instead of taking a source




cenzinj on Γext, ∇h · n = 0 on Γint, (71)
After one hour, the medium containing the enzyme is removed and a fresh medium containing
the molecule of interest is added. Consequently, we choose a Dirichlet boundary condition on c








cdruginj on Γext, ∇c · n = 0 on Γint.
(72a)
(72b)
After a while, the spheroid can be removed from this second medium. In this third case, we set
the outter flux of enzyme and of therapeutic agent to be zero.{ (
D0enz∇h+ hJenz
)
· n = 0 on Γext, ∇h · n = 0 on Γint,(
D0drug∇c+ cJdrug
)
· n = 0 on Γext, ∇c · n = 0 on Γint.
(73a)
(73b)
5.2.2 Effect on porosity
As expected, the porosity remains quasi constant and equal to its initial constant value (0.1 in
this case) when the spheroid is incubated in a medium with no enzyme. On the contrary, it
varies when the tissue is incubated with an ECM degradation enzyme. Thus, at t = 60 minutes,
the ECM has been degraded substantially all over the spheroid, and although the degradation
of the ECM is slightly higher at the boundary, the effect is quite homogeneous (Figure 15a). As
far as the total mass of fluid within the spheroid is concerned, it increases gradually while the
enzyme degrades the ECM (Figure 15b).
5.2.3 Results
ECM degradation enzymes such as collagenase and hyaluronidase where shown to increase the
diffusion of macromolecules in spheroid and in tumor tissue, with a greater impact witnessed in
the case of collagenase compared to hyaluronidase [30]. We performed simulations to evaluate
the effect of an incubation of a spheroid with enzyme on the distribution of drugs with a low
coefficient of diffusion (D0drug = 10−9 ui), such as the one of a macromolecule. We simulate
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(a) Porosity versus radial position at
the end of the incubation phase.

























(b) Quantity of fluid in the tissue versus
time.
Figure 15: Effect on the porosity of a tissue incubated with collagenase (20 U) during 60 minutes
compared to incubated with a saline solution (0 U).
the incubation during 5 minutes with a therapeutic agent one hour after the incubation with
collagenase and we observed the behavior of the drug’s concentration for ten minutes, including
the 5 minutes of incubation. It can be observed that the area where the drug is present above
a certain minimum concentration is wider when the spheroid was previously incubated with
collagenase (Figure 16).























(a) Drug’s total mass in the tissue
versus time.




























(b) Drug’s concentration plotted
versus the postion in the tumor
at time t = 10 minutes.
(c) 2D-drug’s concentration in the tumor
at time t = 10 minutes.
Figure 16: Numerical results for a therapeutic agent with a low coefficient of diffusion incubated
during 5 minutes.
We then performed simulations to evaluate the effect of an incubation of a spheroid with enzyme
on the distribution of drugs with an higher coefficient of diffusion (D0drug = 10−6 ui), such as the
one of a small molecule. In this case, the whole domain is affected with or without pretreatment,
but the degraded ECM has two main effects: the drug reaches the whole domain faster, and
naturally degrades slower which results in a higher concentration of drug throughout the tissue
after 10 minutes (Figure 17).
We finally performed simulations with a quite low coefficient of diffusion (D0drug = 10−8 ui),
but for a tissue incubated longer (15 minutes) and we waited 15 more minutes to look at the
drug’s distribution. In this case, the result is qualitatively in agreement with the experiments
developed by [43] (cf Figure 3): with an enzyme pretreatment, the drug distribution after 30
minutes (including 15 minutes of incubation) is way better than if the tissue was not pretreated
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(a) Drug’s total mass in the tissue
versus time.






























(b) Drug’s concentration plotted
versus the postion in the tumor at
time t = 1 minute.






























(c) Drug’s concentration plotted
versus the postion in the tumor at
time t = 10 minutes.
Figure 17: Numerical results for a therapeutic agent with an higher coefficient of diffusion incu-
bated during 5 minutes.
(Figure 18). The drug is not only present all over the tissue, its concentration is also higher,
improving thus the chances of uptake by the cells.

























(a) Drug’s total mass in the tissue
versus time.




























(b) Drug’s concentration plotted
versus the postion in the tumor
at time t = 30 minutes.
(c) 2D-drug’s concentration in the tumor
at time t = 30 minutes.
Figure 18: Numerical results for a therapeutic agent with a quite low coefficient of diffusion
incubated during 15 minutes.
In the specific framework of an injection of DNA plasmids, a question of interest would be to
determine when to do electrotransfer. If the best moment is when the area where the DNA
plasmids concentration is above a certain minimum concentration is the widest, then the model,
rightfully calibrated, could allow to calculate this optimized time.
5.3 Effect of an ECM degradation enzyme on transcapillary transport
of therapeutic agent
5.3.1 Boundary conditions
Define the portions of the boundary Γext, the surface of the tumor, and Γint the inner boundaries.
On the surface of an isolated tumor, there are no contact forces and the pressure at the outer edge
is the same as the pressure in the surrounding tissue, that we set to zero. On the concentration
of the injected species, we assume that their flux is zero on Γext. To take into account the
axisymmetric geometry of the domain, we choose on the internal boundaries Γint homogeneous
RR n° 9030
32 Manon Deville & others
Table 3: Values of the specific model parameters in the simulations of Section 5. All other
parameters are taken from Table 2.
Parameter Symbol Value Unit Reference
Diffusion coefficient of the enzyme D0enz 10−4 m2/s
Diffusion coefficient of the therapeutic agent D0drug 10−9, 10−6, 10−8 m2/s
Starling’s coefficient γ 5× 10−5 Pa−1s−1 [64]
Fluid/solute coefficient γc 0.9 - [13]
Measure of treatment efficacity K 10−14 m3s−1U−1
Recovery coefficient ar 5× 10−4 s−1
Degradation rate of the enzyme kdenz 1× 10−4 s−1
Degradation rate of the therapeutic agent kddrug 2× 10−4 s−1
Driving pressure Pv 10−1 Pa
Initial values Symbol Initial value Unit
Concentration in drug c(0,x) 0 kg m−3
Pressure incubation case p(0,x) 0 Pa
Neumann conditions on P , h and c and we impose that the displacement will only be radial.
SEs n = 0 on Γext, u · n = 0 on Γint,
P = 0 on Γext, ∇P · n = 0 on Γint,(
D0enz∇h+ hJenz
)
· n = 0 on Γext, ∇h · n = 0 on Γint,(
D0drug∇c+ cJdrug
)





5.3.2 Initial pressure profile
In the simulations, Pv and γ are chosen so the initial pressure profile, derived from equation (63),
fits the type of IFP profile observed in tumors (Figure 19).
(a) Normalized 2D-pressure in the tu-
mor before the experiment.























(b) Normalized pressure in the tumor
before the experiment versus position.
Figure 19: Initial normalized pressure profile. This type of steep profile is in agreement with
previous studies [13].
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5.3.3 Effect on porosity
As it was previously observed in Section 4.2, the porosity remains quasi constant when only a
saline solution is injected. On the contrary, it varies when the tissue is injected with an ECM
degradation enzyme. At t = 60 minutes, we observe that without enzyme, the porosity is equal
to its initial constant value (0.1 in this case) while in presence of enzyme, the ECM has been
degraded substantially all over the tissue. Although the degradation of the ECM is the slightly
higher in the vicinity of the injection point, the effect is quite homogeneous. As expected, the
total mass of fluid within the tissue increases gradually while the enzyme degrades the ECM.




















(a) Porosity versus radial position 60
minutes after the injection.
























(b) Quantity of fluid in the tissue versus
time.
Figure 20: Effect on the porosity of a tumor injected with hyaluronidase (1500 U) compared to
injected with a saline solution (0 U).
5.3.4 Effect on the IFP
The effect of hyaluronidase on IFP was demonstrated experimentally by [29] and [19]. Intra-
tumoral injection of hyaluronidase in tumors reduced IFP in a dose-dependent manner up to
a maximum reduction. However, by increasing the dose further, IFP was reduced to a lesser
extent. An initial increase in IFP was observed, explained by the increase in the volume and
compression of the tissue at the moment of the intratumoral injection.
The simulation reproduces the three main effects observed in the experiments: an initial increase
in IFP due to the intratumoral injection, the fact that IFP reaches a reduced value after some
time and finally the non-linear behavior regarding the concentration.
5.3.5 Results
It was shown that both hyaluronidase and collagenase increase convection by inducing transcapil-
lary pressure gradients in human osteosarcoma xenografts [29, 28]. We have seen previously that
an injection of enzyme has an effect on the IFP, inducing a transcapillary pressure gradient in a
dose-dependent manner up to a maximum reduction. Increasing the dose further, IFP is reduced
to a lesser extent. This reduction was shown to improve both the distribution and the uptake
of drugs in tumors [29]. In this section, we focus on the distribution of drugs. We simulate an
injection during 1 minute of a therapeutic agent one hour after the injection of enzyme and we
observed the behavior of the drug’s concentration for ten minutes, including during the injection.
For all simulatiojns, the same value of cv(t,x) = χ{0≤t≤1 min}(t) cv is taken while different values
of cenzinj previously injected are considered. For a drug with a low coefficient of diffusion, such as
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(a) Normalized IFP versus position at
time t = 60 minutes.






















(b) Normalized IFP versus time.
Figure 21: Effect on the normalized interstitial fluid pressure of a tumor injected with
hyaluronidase (500 U, 1500 U, 3000 U) compared to injected with a saline solution.
the one of a macromolecule, several features are observed. First, the total mass of therapeutic
agent that actually reaches the tumor by transcapillary transport varies with the concentration
of enzyme previously injected (Figure 22a). Second, while without enzyme the therapeutic agent
only penetrates the periphery of the tumor, we observe that with a pretreatment, the therapeutic
agent is present all over the tumor (Figure 22b). Finally, the same non-linear behavior regarding
the concentration of enzyme previously injected is observed. In particular, if the concentration
of enzyme is too high, as the pressure is reduced to a lesser extent, the drug’s penetration in the
tumor by transcapillary transport is also reduced.
























(a) Drug’s total mass in the tissue
versus time.






























(b) Normalized area reached by
a minimal concentration of ther-
apeutic agent versus time.





























(c) Drug’s concentration plotted versus the
postion in the tumor at time t = 5minutes.
Figure 22: Numerical results for a therapeutic agent with a low coefficient of diffusion injected
intravenously.
For a drug with an higher coefficient of diffusion, such as the one of a smaller molecule, the
transcapillary transport in the tumor is also improved, but the main features of interest are
different. In particular, as the drug reaches the whole tumor mainly by diffusion in any case, the
contributions of the pretreatment of the tumor with an ECM degradation enzyme are the same as
the ones developed in the previous subsection concerning spheroids. In particular, it is when the
concentration of enzyme previously injected is the highest that the drug reaches homogeneously
the tumor the fastest and that the natural degradation process is slowed the most. Nevertheless,
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the total mass of therapeutic agent that actually reaches the tumor by transcapillary transport is
consistent with the reduction of IFP in the same non-linear behavior regarding the concentration
of enzyme, and consequently, at t = 10 minutes, the best configuration is also obtained for the
concentration of enzyme that induces the highest reduction in IFP.

























(a) Drug’s total mass in the tissue
versus time.



























(b) Drug’s concentration plotted
versus the postion in the tumor
at time t = 1 minute.
































(c) Drug’s concentration plotted versus the
postion in the tumor at time t = 5minutes.
Figure 23: Numerical results for a therapeutic agent with an higher coefficient of diffusion injected
intravenously.
The distribution of the drug into the tissue is directly correlated with the transcapillary pres-
sure gradient created by the hyaluronidase injected. In particular, it is for the hyaluronidase’s
concentration value for which the maximum pressure reduction is obtained that we obtained the
best distribution profile. Increasing the dose further, the pressure is reduced to a lesser extent
and the consequence on the distribution of drug is that the area where the concentration of
therapeutic agent is above a minimum concentration value is smaller. This result is in agreement
with the experiments described by [29] where hyaluronidase was shown to improve the distribu-
tion of doxorubicin considerably. To go further and consider the possibility of using the model
as a strategie to optimize drug delivery, we would need more experimental data to calibrate the
model parameters.
6 Conclusion
In this paper we developed a novel mathematical formulation to describe the effect of an ECM
degradation enzyme on a soft biological tissue. The principal novelty of our contribution is
the development of a model based on the use of Partial Differential Equations (PDEs) that
incorporates the effect of an ECM degradation enzyme within the general and well established
framework of poroelastic theory of mixtures. Specifically, where usually the fraction volumes
of the different phases are assumed to be constants, we derive evolutive equations to describe
them. Having defined the possible interactions between phases, our approach consists in deriving
a system of conservation laws (mass and linear momentum) for the phases and components of
the mixture that includes the enzyme’s concentration as main determinant of porosity evolution.
The next step was to develop a numerical approximation of the mathematical model introduced
in the article. As the medium is assumed to be poroelastic, it can undergo some deformation
and potentially change of shape if a boundary condition is applied on stress. It was necessary
to formulate our model in a reference fixed domain before developing a computational algorithm
to approximate the system’s solution. Below we address the more significant outcomes of the
conducted simulations.
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1. The illustrated numerical tests conducted in 1D indicate the role of each new parameter
on the porosity evolution.
2. The illustrated numerical results in 2D can describe a well known principle of prefential
flow in the direction of the fiber tracts in the context of a transverse anisotropic media.
3. Model simulations indicate that an intratumoral injection of hyaluronidase results in a
reduction of the IFP in a dose-dependent manner up to a maximum reduction, and that
once that maximum reduction is achieved, a further increase of the dose results in a smaller
reduction. This finding represents a favorable result from the experimentalist point of view,
because it is in agreement with several observations previously reported.
4. The injection of an ECM degradation enzyme was also shown to enhance distribution,
by improving diffusion and/or convection, of drug throughout the tissue. This outcome
reinforces the idea that, used in medicine, these enzymes can improve a treatment by
widening its field of action.
Further research effort will be devoted to calibrating the model’s parameters with additional
experimental data and to considering domains with more complex 3D geometries. An effort will
also be made to rightfully coupled this model with an electrical model in order to explain and
quantify the uptake of DNA plasmids observed by [63].
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Appendix A Formulation of the model in Ω0 in the general
case
The calculus in the general case gives the final system of equations (77). Recall that matrix B
is defined as the inverse of matrix A given by (47). As,













we kept the notation B to refer to B(u) in system (77). Note that we equally dropped bars on








The equivalent system in Ω0 in dimensionless form reads
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where we get (77a) from Assumption 1, (77b) from Equation (21), (77c) from (15), (77d) from
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